T1	Participants 129 187	advanced gastric or gastroesophageal cancer adenocarcinoma
T2	Participants 193 210	V-325 Study Group
T3	Participants 545 580	445 patients were randomly assigned
T4	Participants 1835 1852	in AGGEC patients
